At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed anaplastic astrocytoma
- ✓Tumor subtotally resected or biopsied before treatment with evidence of residual disease on MRI within 2 weeks
- ✓Age 18 and over
- ✓Karnofsky performance status 60-100%
- ✕Brain stem tumors
- ✕Prior chemotherapy or myelosuppressive radiotherapy
- ✕Prior immunotherapy or antineoplaston therapy
- ✕Prior cytodifferentiating agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Adult Brain Tumor. Completed, enrolled 19 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for adults with anaplastic astrocytoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with anaplastic astrocytoma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with anaplastic astrocytoma.
Study Details
Timeline
Interventions
Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).